The ancient place-name for the village of Torredonjimeno

El nombre antiguo (pre-romano o romano) de “Torredonjimeno” (Jaén) sigue siendo objeto de disputa. Para unos sería “Tucci Vetus” y para otros “Abra”. Por otra parte se le atribuye el nombre de “Ossaria” en época visigótica. Finalmente, en el propio “Torredonjimeno” y en general en la provincia de Jaén se da por cierto que su nombre fue “Tosiria”, del que deriva el localicio “Tosiriano” de uso generalizado. En este trabajo tratamos de arrojar luz a este problema toponímico.The ancient (pre-roman or roman) place-name for the village of “Torredonjimeno” (Jaen, in the South of Spain) is actually disputed. For some scholars it would be “Tucci Vetus”, for some others “Abra”. Further on, during the Visigothic time, it would be named “Ossaria”. Finally, in Torredonjimeno and generally speaking, in Jaen province, the names used nowadays are “Tosiria” for the village and “Tosirian” for its inhabitants. The present research work is aimed to bring some light into the problem

El anillo argénteo del Cerro de la Mesa (Toledo) y los anillos con caballito de la Hispania prerromana

Sin resume

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio